Lachlan Brown

Stock Analyst at Rothschild & Co

(1.43)
# 3,420
Out of 5,182 analysts
14
Total ratings
36.36%
Success rate
-3.2%
Average return

Stocks Rated by Lachlan Brown

SPS Commerce
Apr 16, 2026
Downgrades: Neutral
Price Target: $100$60
Current: $55.44
Upside: +8.23%
The Descartes Systems Group
Apr 16, 2026
Upgrades: Buy
Price Target: $100$90
Current: $70.94
Upside: +26.88%
Eupraxia Pharmaceuticals
Mar 23, 2026
Initiates: Outperform
Price Target: n/a
Current: $7.16
Upside: -
Viridian Therapeutics
Dec 3, 2025
Initiates: Outperform
Price Target: n/a
Current: $13.41
Upside: -
Manhattan Associates
Jun 10, 2025
Downgrades: Neutral
Price Target: $270$200
Current: $141.09
Upside: +41.75%
Harrow
Jun 10, 2025
Initiates: Outperform
Price Target: n/a
Current: $40.52
Upside: -
Kalaris Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: n/a
Current: $5.89
Upside: -
Ocular Therapeutix
Apr 8, 2025
Initiates: Outperform
Price Target: n/a
Current: $9.53
Upside: -
Synopsys
Jan 13, 2025
Initiates: Buy
Price Target: $600
Current: $482.93
Upside: +24.24%
Cadence Design Systems
Jan 13, 2025
Initiates: Buy
Price Target: $350
Current: $329.58
Upside: +6.20%
Initiates: Outperform
Price Target: n/a
Current: $40.95
Upside: -